Related references
Note: Only part of the references are listed.HPV vaccine cross-protection: Highlights on additional clinical benefit
Rosa De Vincenzo et al.
GYNECOLOGIC ONCOLOGY (2013)
High-Throughput Pseudovirion-Based Neutralization Assay for Analysis of Natural and Vaccine-Induced Antibodies against Human Papillomaviruses
Peter Sehr et al.
PLOS ONE (2013)
Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China
Jianhui Nie et al.
JOURNAL OF VIROLOGICAL METHODS (2012)
Implementation of Human Papillomavirus Immunization in the Developing World
Mark A. Kane et al.
VACCINE (2012)
Global Burden of Human Papillomavirus and Related Diseases
David Forman et al.
VACCINE (2012)
A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines
John T. Schiller et al.
VACCINE (2012)
Evaluation of the HPV 18 antibody response in Gardasil® vaccinees after 48 months using a pseudovirion neutralization assay
Christine C. Roberts et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine up to 8.4 years of follow-up
Cecilia M. Roteli-Martins et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Analyses of Human Papillomavirus Genotypes and Viral Loads in Anogenital Warts
Siolian L. R. Ball et al.
JOURNAL OF MEDICAL VIROLOGY (2011)
The first international standard for antibodies to HPV 16
Morag Ferguson et al.
VACCINE (2011)
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
Hans-Ulrich Bernard et al.
VIROLOGY (2010)
Detection of HPV types and neutralizing antibodies in women with genital warts in Tianjin City, China
Xue-ling Wu et al.
VIROLOGICA SINICA (2010)
Detection of HPV Types and Neutralizing Antibodies in Gansu Province, China
Xueling Wu et al.
JOURNAL OF MEDICAL VIROLOGY (2009)
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years
Tino F. Schwarz et al.
VACCINE (2009)
Quantitation of Human Seroresponsiveness to Merkel Cell Polyomavirus
Diana V. Pastrana et al.
PLOS PATHOGENS (2009)
Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types
Raeda Z. Rizk et al.
JOURNAL OF GENERAL VIROLOGY (2008)
Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes
Kazunari Kondo et al.
JOURNAL OF MEDICAL VIROLOGY (2008)
Duration of humoral immunity to common viral and vaccine antigens
Ian J. Amanna et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A Highly Sensitive Assay for Monitoring the Secretory Pathway and ER Stress
Christian E. Badr et al.
PLOS ONE (2007)
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
Sven-Eric Olsson et al.
VACCINE (2007)
Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV 16 minor capsid protein L2 surface region
Kazunari Kondo et al.
VIROLOGY (2007)
Evaluation of the thermal stability of Gardasil®
Mary L. Shank-Retzlaff et al.
HUMAN VACCINES (2006)
Factors influencing subcellular localization of the human papillomavirus L2 minor structural protein
E Kieback et al.
VIROLOGY (2006)
Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins
T Waterboer et al.
CLINICAL CHEMISTRY (2005)
Correlation between Mouse Potency and In Vitro Relative Potency for Human Papillomavirus Type 16 Virus-Like Particles and Gardasil® Vaccine Samples
M. Shank-Retzlaff et al.
HUMAN VACCINES (2005)
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2
DV Pastrana et al.
VIROLOGY (2005)
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18
DV Pastrana et al.
VIROLOGY (2004)
Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells
N Mossadegh et al.
VIROLOGY (2004)
Efficacy and other milestones for human papillomavirus vaccine introduction
SR Pagliusi et al.
VACCINE (2004)
Efficient intracellular assembly of papillomaviral vectors
CB Buck et al.
JOURNAL OF VIROLOGY (2004)
Recombinant Gaussia luciferase.: Overexpression, purification, and analytical application of a bioluminescent reporter for DNA hybridization
M Verhaegen et al.
ANALYTICAL CHEMISTRY (2002)
Occupancy and mechanism in anti body-mediated neutralization of animal viruses
PJ Klasse et al.
JOURNAL OF GENERAL VIROLOGY (2002)
Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells
JR Mascola et al.
JOURNAL OF VIROLOGY (2002)
Enhancement of capsid gene expression:: Preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes
C Leder et al.
JOURNAL OF VIROLOGY (2001)
Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles
TJ Palker et al.
VACCINE (2001)
Share Paper
